Nasal Calcium Channel Blocker Dosing for Rapid Arrhythmia Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiac arrhythmias such as PSVT and atrial fibrillation, as well as angina and migraines, are often invasive or inefficient, lacking effective self-administered therapies for rapid symptom relief during episodes.
Innovation Solution
A two-dose regimen of a pharmaceutically acceptable acetate or methanesulfonate salt of compound I, administered nasally at concentrations of 350 mg/mL±50 mg/mL, with the second dose given between 5-25 minutes after the first to enhance cardiac rhythm normalization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a single dose of calcium channel blocker is administered, then the treatment is simple, but the efficacy in terminating cardiac arrhythmia is insufficient
Solution Approach 1:
The treatment is divided into multiple discrete doses (first dose and second dose) administered at a specific time interval (5-25 minutes apart). This segmentation allows the first dose to be evaluated for efficacy, with the second dose serving as a booster if the arrhythmia persists, thereby improving overall termination efficacy while maintaining operational simplicity through clear dosing instructions
Solution Approach 2:
The dosing regimen employs periodic administration with a defined interval (5-25 minutes) between doses. This periodic action optimizes drug concentration timing to enhance arrhythmia termination efficacy while maintaining simple operational protocols through standardized dosing schedules
2Speed
If high concentration of drug is administered rapidly, then rapid symptom relief is achieved, but side effects may increase
Solution Approach 1:
The total drug dose is segmented into multiple administrations (first dose and potential second dose) separated by a time interval. This segmentation delivers the necessary high concentration for rapid arrhythmia termination while distributing the total exposure to reduce side effect risk
Solution Approach 2:
The regimen provides a first dose that may be sufficient for some patients, with a second dose available if needed. This partial action approach achieves rapid relief for responsive patients while avoiding excessive total dosing that would increase side effects, allowing individualized treatment intensity
3Reliability
If invasive procedures are used to treat cardiac arrhythmia, then treatment efficacy is improved, but patient comfort and accessibility deteriorate
Solution Approach 1:
The nasal spray formulation enables patients to self-administer the medication without requiring invasive procedures or hospital-based interventions. This self-service approach maintains treatment efficacy through effective drug delivery while dramatically improving patient accessibility and comfort
Solution Approach 2:
The invention replaces invasive mechanical or surgical intervention systems with a non-invasive pharmacological delivery system (nasal spray). This substitution achieves comparable treatment efficacy for arrhythmia termination while eliminating the invasiveness and associated patient discomfort
Data Source
AI summary
The present invention is related to methods of treating cardiac arrhythmia, angina, or a migraine in a patient in need thereof, with a therapeutically effective amount of a compound having a structure according to the formula:the method comprising nasally administering to the patient (i) a first dose, and (ii) a second dose of an aqueous composition comprising a pharmaceutically acceptable acetate or methanesulfonate salt of compound I, or a racemate or enantiomer thereof, wherein the acetate or methanesulfonate salt of compound I, or the racemate or enantiomer thereof, is dissolved in the aqueous composition at a concentration of 350 mg/mL±50 mg/mL, and wherein the second dose of the compound is administered between 5 minutes and 25 minutes after the first dose.